Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase

A 52-year-old man was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). He experienced bosutinib-induced pulmonary arterial hypertension (PAH) recurrence following dasatinib use. Symptoms and examination findings associated with PAH improved after bosutinib cessation. Although n...

Full description

Bibliographic Details
Main Authors: Ibuki Takatsuka, Hiroya Hirata, Takumi Takahashi, Satoshi Dohtan, Shinichiro Oka, Nami Sakamoto, Masamitsu Takaba, Miwa Adachi, Tomonari Takemura, Yasuyuki Nagata, Takaaki Ono
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Leukemia Research Reports
Subjects:
Pulmonary arterial hypertension
Dasatinib
Bosutinib
Nilotinib
Chronic myeloid leukemia in chronic phase
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048922000243

Internet

http://www.sciencedirect.com/science/article/pii/S2213048922000243

Similar Items